HomeNewsBusinessCOVID-19 lockdown | NBFC-MFIs stare at liquidity shock: Will RBI step in?

COVID-19 lockdown | NBFC-MFIs stare at liquidity shock: Will RBI step in?

The lock-down announced in late March to fight Covid-19 spread has hit the industry bad. NBFC-MFIs are also looking at the likelihood of high bad loans as lock-down could result in major income loss of small borrowers.

April 17, 2020 / 09:06 IST
Story continues below Advertisement
LIVE updates of the Reserve Bank of India (RBI)'s Monetary Policy Committee (MPC) decisions
LIVE updates of the Reserve Bank of India (RBI)'s Monetary Policy Committee (MPC) decisions

The COVID-19 lock-down may erode upto 25 percent of the annual collections of NBFC-MFIs, industry fear. This is significant for microlenders since the average loan tenure of NBFC-MFI borrowers is just 18-24 months. For banks, this is much longer. The liquidity vacuum thus created will hit these companies hard. MFIs borrow money at about 10-12 percent from banks and charge about 23 percent interest rate from borrowers. These entities collect payments in cash.

The average loan ticket size of Rs 31,000 crore. There are 54 NBFC-MFIs in the country with about 5.6 crore microfinance borrowers. Indian microlenders have a total loan book of Rs2.16 crore out of which NBFC-MFIs have Rs 73,000 crore. According to the data from the Reserve Bank of India (RBI), outstanding loans to the entire NBFC sector from banks stand at Rs 7 lakh crore. On a year-on-year basis, this exposure has grown by 22 percent. That is a significant exposure.

Story continues below Advertisement

“This will seriously impact our liquidity position and curtail the ability to issue fresh loans when demand picks up,” said Harsh Shrivastava, chief executive of Microfinance Institutions Network, MFIN to Moneycontrol. “We have stopped collections since all NBFC-MFIs are obliged to offer moratorium for borrowers,” said Shrivasatava.

On March 27, the RBI asked all lending institutions to offer a three-month loan moratorium to borrowers on all term loans. That includes NBFCs. But NBFCs are not permitted to avail the same facility from banks, from whom they borrow money for operations. This lack of level-play put them in a tough spot.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show